1163287-01-1 Usage
General Description
Methyl 4-fluoro-2-methyl-5-nitrobenzoate 98% is a chemical compound known for its high purity of 98%. This organic compound is often used in various chemical reactions and experiments due to its specific properties. Its structure consists of a benzoate ester backbone with the addition of other functional groups: a nitro group, a fluorine atom, and an additional methyl group. This results in a compound that has both the reactive properties of nitro compounds and the stability offered by fluoro compounds. The percentage (98%) indicates the concentration, suggesting that the substance is relatively pure with minimal impurities. It has a molecular formula of C9H8FNO4. Details such as its physical and chemical properties can vary depending on conditions such as temperature and pressure.
Check Digit Verification of cas no
The CAS Registry Mumber 1163287-01-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,6,3,2,8 and 7 respectively; the second part has 2 digits, 0 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1163287-01:
(9*1)+(8*1)+(7*6)+(6*3)+(5*2)+(4*8)+(3*7)+(2*0)+(1*1)=141
141 % 10 = 1
So 1163287-01-1 is a valid CAS Registry Number.
1163287-01-1Relevant articles and documents
INDAZOLES AS LRRK2 INHIBITORS
-
Page/Page column 85, (2020/10/09)
The present invention is directed to indazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.
HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS
-
Paragraph 000151; 000152, (2015/10/05)
ABSTRACT The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound.
HETEROCYCLIC COMPOUNDS FOR THE INHIBITION OF PASK
-
, (2012/11/08)
Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.
